Eli Lilly has released data showing that two of its antibodies used in combination can reduce hospitalization and death from COVID-19. There were a total of 11 hospitalizations and deaths among over 1000 participants taking the drugs, bamlanivimab and etesevimab, compared to 36 in a control group, which represents a 70% reduction. Ten deaths in total occurred, all from the control group receiving placebo.